Management of chronic myeloid leukaemia in lymphoid blast transformation.
METHODS
We designed a chemotherapy schedule similar to that used in childhood acute lymphoblastic leukaemia for the management of patients with Philadelphia chromosome positive chronic myeloid leukaemia in lymphoid blast transformation. It includes the use of intensive systemic chemotherapy and intrathecal methotrexate followed by 'maintenance' chemotherapy for 2 years or allogeneic bone marrow transplantation.


CONCLUSIONS
Of the four patients treated with this schedule, two survive at 30 and 36 months from transformation respectively. The overall median survival is 19 months. A coordinated approach to this relatively rare clinical problem may be useful.
LRF Leukaemia Unit, Royal Postgraduate Medical School, London, United Kingdom.
A C
AC
Nathwani
J M
JM
Goldman
D000328:Adult; D016026:Bone Marrow Transplantation; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000601:surgery; D008213:Lymphocyte Activation; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D012074:Remission Induction
D008727:Methotrexate